Company to discuss glycan-targeting ADC platform during BIO International Convention 2025. NEW TAIPEI CITY, Taiwan I June 12, 2025 I GlycoNex, Inc. (4168, hereinafter referred to ...

LEHI, UT, USA I June 12, 2025 I Biolexis Therapeutics, Inc. ( a clinical-stage therapeutics company pioneering next-generation treatments ...

BOSTON, MA, USA I June 12, 2025 I EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, a leading science and ...

Research program combining Debiopharm’s AbYlink™ conjugation technology with Alkyon’s modular antibody platform and novel targeting approaches is set to drive ...

Breakthrough in AI-powered drug discovery validates HYFT™-driven peptide design, with broad potential across multiple therapeutic areas ...

KRAKOW, Poland I June 12, 2025 I Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that ...

MAINZ and TÜBINGEN, Germany I June 12, 2025 I BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they ...

MOBILIZE-1 is the first Phase 3 study being initiated for V181 as part of a planned robust clinical development program ...

BASEL, Switzerland I June 12, 2025 I Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of ...

SAN DIEGO, CA, USA I June 11, 2025 I Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company dedicated to advancing in vivo ...

BARCELONA, Spain I June 11, 2025 I SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations ...

COPENHAGEN, Denmark I June 12, 2025 I SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for ...